Well I already covered OSIP in the pre-market. I've taken it off my screen so that I'm not tempted to try to get my money back by going long it. I guess I'm due for one of these disasters every couple of years. I think this is the second time something like this has happened in 5 years. I was already not feeling like trading today because of options expiration and the fact that I'm still tired from last night. Now I'm really not feeling like doing anything today. I may just watch the first hour and call it a day.
Currently holding:
Long - AAPL, CME, FBR, FORM, MYGN, URBN
Short - ADI, covered OSIP in the pre-market
Looking for swing trade entries in:
Longs - CREAF
Shorts - JOSB, KOSP, RI, SCSS
Potential day trades:
(From Briefing.com)
Gapping Down
PLMO -16% (Merrill and Bear Stearns downgrades following NovQ report and guidance), AZN -8.7% (AstraZeneca's Iressa has poor test results), LF -16% (cuts forecast, significantly below expectations), EFII -11% (Merrill downgrade following lowered guidance), CDSS -32% (guides below consensus), ELON -6% (cut to Sell from Neutral at Opco), CC -5% (reports NovQ), COMS -4% (reports NovQ), TTWO -2.8% (misses by $0.19, guides below consensus), ADBE -2.6% (reports NovQ), SANM -2.2% (reports delay in filing of 10-K).... Under $3: ANLT -20% (auditor issues a going concern qualification), WAVX -18% (to complete $5.8 mln offering under $25 mln shelf registration).
Gapping Up
Some biotechs are up big on news that AstraZeneca's Iressa poor test results: OSIP +47%, DNA +6.8%, IMCL +4.5%.... Other News: JOBS +5.6% (highlighted favorably in IBD), CNLG +19% (receives approval from two major Canadian utilities), BLDP +11% (announces CDN$55 mln investment by DCX and Ford), GEPT +10% (announces $2 mln order), GORX +10% (provides Mucotrol update), STEM +6.7%, NKE +4.8% (reports NovQ), AIG +2.1%... Under $3: MCLD +75% (enters multi-year agreement with MCI), DYTK +28% (co expects to exceed quarterly rev target), ICOR +28% (receives notice of allowance on metabolomics patent), UVSL +26%, POCI +21%.
